Innodem, Novartis agree to continue developing eye-tracking technology
ETNA would allow a tablet to noninvasively measure MS disease progression
Innodem Neurosciences has signed a multi-year agreement with Novartis Canada to continue developing Innodem’s digital biomarker eye-tracking technology, a noninvasive method to monitor disease progression in multiple sclerosis (MS).
The multimillion-dollar commercial agreement comes on the heels of promising data from an observational trial, sponsored by the two companies, that tested the technology — dubbed Eye Tracking Neurological Assessment, or ETNA — in people with MS.
The application, which runs on regular home tablets and is powered by artificial intelligence (AI), confirmed the links between eye movement and MS clinical assessments. It also showed that eye-tracking technology can measure disease severity and cognitive status in MS participants.
“In the past year, the non-invasive, mobile ETNA technology was used by people living with MS during an observational trial where they were able to self-test at home because of the powerful processing capabilities of today’s off-the-shelf tablets,” Marc Reeves, co-founder and chief business officer of Innodem, said in a company press release. “With the test results and using AI models, we were able to replicate similar findings of past published academic research papers demonstrating how eye tracking can be used to monitor MS disease status and progression.”
https://multiplesclerosisnewstoday.c...ng-technology/
ETNA would allow a tablet to noninvasively measure MS disease progression
Innodem Neurosciences has signed a multi-year agreement with Novartis Canada to continue developing Innodem’s digital biomarker eye-tracking technology, a noninvasive method to monitor disease progression in multiple sclerosis (MS).
The multimillion-dollar commercial agreement comes on the heels of promising data from an observational trial, sponsored by the two companies, that tested the technology — dubbed Eye Tracking Neurological Assessment, or ETNA — in people with MS.
The application, which runs on regular home tablets and is powered by artificial intelligence (AI), confirmed the links between eye movement and MS clinical assessments. It also showed that eye-tracking technology can measure disease severity and cognitive status in MS participants.
“In the past year, the non-invasive, mobile ETNA technology was used by people living with MS during an observational trial where they were able to self-test at home because of the powerful processing capabilities of today’s off-the-shelf tablets,” Marc Reeves, co-founder and chief business officer of Innodem, said in a company press release. “With the test results and using AI models, we were able to replicate similar findings of past published academic research papers demonstrating how eye tracking can be used to monitor MS disease status and progression.”
https://multiplesclerosisnewstoday.c...ng-technology/
Comment